A US FDA advisory committee meeting Sept. 14 to review new pediatric study data for Purdue Pharma LP's Butrans (buprenorphine extended-release) seems aimed at heading off the type of public outcry that followed approval of a pediatric claim for the company's OxyContin (oxycodone extended-release).
FDA is asking its Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management advisory committees to discuss a...